Effects of Feitai Capsule on quality of life in patients with advanced non-small-cell lung cancer: A randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 7, Issue 7, 2009, Pages 611-615

  Liu, Zhi Zhen ^a   Yu, Zong Yang ^a   Ouyang, Xue Nong ^a   Dai, Xi Hu ^a   Chen, Xi ^a   Zhao, Zhong Quan ^a   Wang, Wen Wu ^a   Li, Jie ^a   Tu, Hua ^a   Ye, Lei ^a   Yan, Yan ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Compound (traditional Chinese drug); Non small cell lung carcinoma; Quality of life; Randomized controlled trial

Indexed keywords

FEITAI EXTRACT; HERBACEOUS AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BRONCHUS MUCUS; CANCER STAGING; CHINESE MEDICINE; CLINICAL FEATURE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; ENERGY; FEMALE; HEMOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TRADITIONAL MEDICINE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPSULES; CARCINOMA, NON-SMALL-CELL LUNG; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHYTOTHERAPY; QUALITY OF LIFE;

EID: 73849116765     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20090703     Document Type: Article

References (8)

1. Lin LZ, Zhou DH, Zheng XT. Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006, 26(5): 389-393. Chinese with abstract in English.
2. Zhou YM, Piao BK, Hou W, Lin HS, Hua BJ, Xiong L, Zheng HG. Clinical observation of Feiliuping ointment on immune state and prognosis in patients with non-small-cell lung cancer. Zhongguo Zhong Yi Yao Xin Xi Za Zhi. 2008, 15(5): 78-79. Chinese.
3. Zheng XY. Guidelines of clinical research on Chinese new herbal medicines. Beijing: Medical Science and Technology Publishing House of China. 2002: 216-221. Chinese.
4. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995, 12(3): 199-220.
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline. J Clin Oncol. 2004, 22(2): 330-353.
6. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979, 63 (11-12): 1727-1733.
7. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M, Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006, 52(2): 155-163.
8. Fathi AT, Brahmer JR. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008, 20(3): 210-216.